This week sees the start of the American Society of Clinical Oncology Symposium on Genitourinary Cancers (ASCO GU) in San Francisco.

Prostate cancer has certainly been in the minds of investors the past few weeks in anticipation of the COMET-1 prostate cancer trial results for cabozantinib (Cometriq).

The share price went on a run-up until Exelixis CEO Michael Morrissey took yet another trip to the biotech ATM machine.  Somehow, this doesn’t come as any surprise given past performance.  The key issue at stake here, however, is will the COMET-1 trial be positive or negative?  The outcome is much anticipated and will no doubt influence the chances of successful approval for cabozantinib in advanced prostate cancer.  Data is expected sometime in first half of this year.

What we can expect in the media this week is more news on the Medivation and Astellas phase 3 trial PREVAIL clinical trial of enzalutamide (Xtandi) in men with advanced prostate cancer who had not yet received chemotherapy.  The ASCO GU abstracts are publicly available at 5pm on Tuesday.

Currently, the key data from oncology medical conferences is focused squarely on Medivation’s enzalutamide and the PREVAIL data.  It seems a good idea to discuss what are the key things to watch out for?

You can sign in or sign-up below to read the report.

 ASCO GU 2014: Why does the Medivation PREVAIL trial matter?

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $399 for 3 months access, $1200 for 12 months access and for a limited time $2000 for 2 years. Subscriptions do not auto renew. Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals contained within it.